Behcet's syndrome: Bechet disease (BD) is a chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular and central nervous system manifestations.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
109 |
4. Check minimum number of eventsNone |
109 |
5. Include endpointsNone |
109 |
6. Filter based on genotype QC (FinnGen only) |
109 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M35
- Name in latin
- Morbus Behçet
Similar endpoints
↥List of similar endpoints to
Behçet disease
based on the number of shared cases.
Similar with more cases:
- Other systemic involvement of connective tissue (FG)
- Other systemic involvement of connective tissue
- Systemic connective tissue disorders
- Finngen Rheumatological endpoints
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 612 | 415 | 187 |
| Only index persons | 535 | 378 | 157 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 53.29 | 53.02 | 54.96 |
| Only index persons | 51.23 | 50.44 | 53.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 109 | 82 | 27 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | 46.74 | 44.78 | 52.72 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 103
- Matched controls
- 1027
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.2
ICD-10 Finland
Behçet disease
+∞
137.8
99
*
L04AX01
ATC
azathioprine; systemic
43.2
34.1
42
16
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
17.1
27.6
47
48
H02AB06
ATC
prednisolone; systemic
11.0
24.8
85
309
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
17.2
24.7
41
38
K12.00
ICD-10 Finland
Recurrent oral aphthae
52.0
18.1
21
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.3
17.0
62
198
M35.3
ICD-10 Finland
Polymyalgia rheumatica
35.8
14.4
18
6
N77.8*M35.2
ICD-10 Finland
Ulceration of vulva in Behçet's disease
+∞
13.9
13
*
H02AB07
ATC
prednisone; oral
6.6
12.5
35
74
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.8
12.0
22
23
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
9.7
11.7
24
31
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
+∞
11.7
11
*
P01BA02
ATC
hydroxychloroquine; oral
7.9
10.0
23
36
N76.6
ICD-10 Finland
Ulceration of vulva
33.6
9.6
12
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
9.5
9
*
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
12.4
9.2
16
15
K12.10
ICD-10 Finland
Stomatitis NOS
54.8
8.8
10
*
L04AA01
ATC
[U] ciclosporin; systemic
54.8
8.8
10
*
L04AD01
ATC
ciclosporin; systemic
30.4
8.7
11
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
8.4
8
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.1
8.2
18
26
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
8.2
56
265
M05BA04
ATC
alendronic acid; oral
6.5
8.1
21
39
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.7
7.9
41
157
H20.1
ICD-10 Finland
Chronic iridocyclitis
48.8
7.8
9
*
M13.9
ICD-10 Finland
Arthritis, unspecified
7.6
7.8
18
28
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
20.3
7.8
11
6
ZX120
NOMESCO Finland
Intravenous
5.9
7.5
21
43
R50.9
ICD-10 Finland
Fever, unspecified
4.2
7.4
30
92
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
7.4
7
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
12.2
7.0
12
11
UJF30
NOMESCO Finland
Ileoscopy through colon
5.3
7.0
21
47
H04.10
ICD-10 Finland
Dry eye syndrome
5.1
7.0
22
52
R1250
NOMESCO Finland
Evaluation of functional capability
18.2
6.9
10
6
N02AX02
ATC
tramadol; systemic, rectal
3.1
6.9
53
265
J05AB11
ATC
valaciclovir; oral
4.5
6.8
25
69
UJF92
NOMESCO Finland
Capsular endoscopy
24.4
6.8
9
*
A07EC01
ATC
sulfasalazine; oral, rectal
5.7
6.8
19
39
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.3
6.7
17
31
M35.7
ICD-10 Finland
Hypermobility syndrome
74.3
6.5
7
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
4.9
6.5
21
51
M05BA07
ATC
risedronic acid; oral
10.3
6.5
12
13
L88
ICPC
Rheumatoid/seropositive arthritis
11.0
6.2
11
11
J01FF01
ATC
clindamycin; systemic
3.1
6.1
39
169
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
11
20.71
23.46
1.3
1.4
—
—
—
0
0
17
18
11.00
14.72
1.5
1.4
—
—
—
0
0
17
20
9.89
13.63
2.4
1.5
—
—
—
0
0
15
5
34.36
12.00
1.4
1.4
—
—
—
0
0
15
5
34.36
12.00
1.4
1.4
—
—
—
0
0
15
6
28.64
11.49
1.4
1.3
—
—
—
0
0
15
6
28.64
11.49
1.4
1.3
—
—
—
0
0
15
6
28.64
11.49
1.4
1.3
—
—
—
0
0
14
17
9.30
10.86
3.6
2.4
—
—
—
0
0
32
99
4.16
9.55
1.8
1.8
2.5
2.4
g/l
0.44
27
87
12
14
9.51
9.53
1.2
1.2
—
—
—
0
0
11
12
10.08
9.13
3.4
2.0
74.4
271.1
ug/l
1.28
11
12
62
313
3.27
8.54
5.1
4.2
35.5
36.2
g/l
0.41
57
297
65
341
3.24
8.33
3.2
2.1
79.5
75.1
nmol/l
0.55
58
308
10
11
9.91
8.21
1.2
1.4
—
—
—
0
0
10
11
9.91
8.21
1.1
1.0
—
—
—
0
0
68
373
3.19
7.95
12.9
7.6
1.2
1.2
mmol/l
0.23
57
317
10
12
9.07
7.70
1.2
1.2
—
—
—
0
0
12
19
6.97
7.41
1.8
1.2
—
—
—
0
0
19
49
4.49
7.06
2.7
1.5
—
—
—
0
0
10
14
7.76
6.82
1.4
1.1
—
—
—
0
0
54
280
2.84
6.66
5.3
2.6
—
—
—
0
0
17
42
4.61
6.64
2.3
1.4
—
—
—
0
0
14
32
4.87
5.96
2.5
1.4
—
—
—
0
0
13
29
4.95
5.68
1.2
1.4
—
—
—
0
0
8
7
12.20
4.86
1.3
1.3
—
—
—
0
0
12
29
4.53
4.76
1.4
1.3
—
—
—
0
0
40
208
2.46
4.58
2.7
3.1
533.2
973.8
ng/l
0.99
30
170
36
183
2.44
4.30
2.9
1.9
3.0
2.9
mg/l
0.11
31
158
28
127
2.62
4.23
4.0
1.6
—
—
—
0
0
7
7
10.57
4.07
1.0
1.3
—
—
—
0
0
37
196
2.34
4.00
3.1
2.9
321.0
4334.5
umol/l
0.80
32
166
63
418
2.20
3.92
8.4
4.4
0.0
0.0
estimate
0.00
13
83
63
421
2.18
3.82
6.3
3.2
0.0
0.0
estimate
0.00
13
82
6
5
12.58
3.81
1.0
1.2
—
—
—
0
0
62
417
2.13
3.64
6.3
3.1
0.0
0.0
estimate
0.00
12
84
9
17
5.66
3.59
2.1
3.2
4.0
3.9
g/l
—
9
17
6
6
10.48
3.54
1.0
1.3
—
—
—
0
0
6
6
10.48
3.54
1.0
1.3
—
—
—
0
0
37
210
2.15
3.31
1.7
1.3
0.6
1.8
u/ml
—
10
50
29
150
2.27
3.25
1.4
1.2
11.6
37.4
iu/ml
—
7
50
25
123
2.34
3.13
3.9
2.2
1.8
3.7
e6/l
0.73
18
57
8
16
5.30
3.11
1.0
1.1
—
—
—
0
0
9
21
4.57
3.07
1.7
1.4
—
—
—
0
0
8
17
4.99
2.98
2.1
4.3
0.0
0.0
g/l
—
8
17
8
17
4.99
2.98
2.1
4.3
0.0
0.0
g/l
—
8
17
9
22
4.36
2.95
1.7
1.1
—
—
—
0
0
6
9
6.98
2.90
1.0
1.2
—
—
—
0
0
8
18
4.71
2.85
2.1
4.2
0.0
0.0
g/l
—
8
18
19
86
2.46
2.84
2.8
1.5
—
—
—
0
0
20
93
2.41
2.82
7.4
7.1
—
—
—
0
0
5
6
8.65
2.77
1.6
2.0
—
—
—
0
0
5
6
8.65
2.77
1.8
1.0
—
—
—
0
0
5
6
8.65
2.77
1.0
1.3
—
—
—
0
0
18
81
2.46
2.72
2.9
1.8
1413.0
28.4
u/l
0.47
13
66
24
124
2.20
2.67
2.8
3.2
507.6
125.5
ng/l
0.34
14
92
42
268
1.92
2.65
3.0
3.3
2.3
2.4
mmol/l
0.61
35
241
9
25
3.83
2.64
2.9
2.3
95.1
93.7
%
—
9
25
8
20
4.23
2.62
1.6
1.4
—
—
—
0
0
8
20
4.23
2.62
1.6
1.4
—
—
—
0
0
33
195
1.99
2.59
2.5
1.7
1.2
0.9
mg/l
0.20
25
148
6
11
5.70
2.58
1.2
1.2
—
—
—
0
0
5
7
7.41
2.57
1.8
1.1
—
—
—
0
0
7
16
4.60
2.52
1.6
1.3
—
—
—
0
0
18
85
2.34
2.45
2.9
1.6
—
—
—
0
0
8
22
3.84
2.41
2.1
3.6
—
—
—
0
0
61
452
1.79
2.31
9.8
6.1
9.2
9.8
umol/l
0.67
56
425
5
9
5.76
2.23
2.0
2.2
—
—
—
0
0
19
97
2.16
2.16
1.6
2.1
4.2
6.0
umol/l
0.77
13
79
46
319
1.76
2.14
4.4
3.5
25.6
53.5
ng/l
0.79
26
196
5
10
5.18
2.09
1.2
1.3
—
—
—
0
0
13
57
2.45
2.07
2.5
4.8
4.1
4.5
pmol/l
0.73
13
51
6
15
4.17
2.07
1.3
1.1
—
0.9
—
0
6
44
306
1.73
2.01
2.2
1.8
106.2
97.9
pmol/l
0.56
30
151
38
254
1.76
1.99
2.6
2.7
51.9
56.6
u/l
0.55
33
230
6
16
3.90
1.96
8.3
1.8
—
—
—
0
0
6
16
3.90
1.96
7.8
1.8
—
—
—
0
0
5
11
4.71
1.96
2.2
2.1
—
—
—
0
0
24
142
1.89
1.84
3.5
2.0
0.4
0.9
e6/l
1.16
18
75
98
869
2.27
1.83
28.6
13.9
139.5
139.8
mmol/l
0.51
93
843
13
62
2.25
1.73
5.0
2.9
2.4
2.8
mmol/l
0.15
13
50
5
13
3.98
1.73
1.0
1.4
—
—
—
0
0
99
887
2.27
1.70
34.2
11.7
14.2
22.3
mg/l
3.11
90
668
31
210
1.67
1.50
2.2
1.6
—
—
—
0
0
9
38
2.49
1.49
27.1
5.0
26.1
26.2
mmol/l
—
9
38
9
38
2.49
1.49
2.3
2.5
1.3
1.3
%
—
9
38
15
81
1.99
1.49
1.7
1.8
—
—
—
0
0
7
28
2.60
1.48
1.3
1.1
—
—
—
0
0
7
28
2.60
1.48
1.3
1.1
—
—
—
0
0
53
412
1.56
1.46
3.9
4.4
—
—
—
0
0
44
328
1.57
1.45
6.3
3.2
—
—
—
0
0
23
145
1.74
1.44
2.0
1.7
831.9
1182.0
nmol/l
1.07
17
108
30
206
1.63
1.38
3.4
2.2
—
—
—
0
0
8
35
2.39
1.30
7.0
1.7
—
—
—
0
0
23
150
1.68
1.28
1.4
1.3
40.3
9.5
u/ml
—
6
62
32
230
1.55
1.21
7.8
3.4
0.0
0.0
estimate
0.00
13
82
10
50
2.10
1.21
1.0
1.0
—
—
—
0
0
8
39
2.13
1.18
1.3
1.4
—
—
—
0
0
14
81
1.84
1.15
3.2
3.2
—
—
—
0
0
12
66
1.92
1.14
1.6
1.8
—
—
—
0
0
7
31
2.34
1.12
2.1
1.5
—
—
—
0
0
8
41
2.03
1.11
2.5
1.5
—
—
—
0
0
90
817
1.58
1.00
23.9
10.7
86.6
85.9
ml/min/173m2
0.09
85
656
10
54
1.94
1.00
1.4
1.2
—
—
—
0
0
25
186
1.45
0.79
1.5
1.4
—
—
—
0
0
12
76
1.65
0.75
1.4
4.4
2.4
7.8
ug/l
—
5
60
15
101
1.56
0.75
4.4
3.7
28.0
32.0
%
—
9
69
7
42
1.71
0.70
32.3
11.5
1.1
1.5
%
—
7
42
7
42
1.71
0.70
32.3
11.5
0.4
0.7
%
—
7
42
79
841
0.78
0.49
4.4
4.0
4.8
4.7
mmol/l
0.26
74
790
73
779
0.81
0.42
5.8
5.1
38.2
39.2
mmol/mol
0.41
73
737
81
854
0.80
0.40
4.6
4.5
2.7
2.8
mmol/l
0.56
76
797
9
68
1.35
0.39
1.2
1.5
—
—
—
0
0
5
37
1.37
0.24
1.2
1.3
—
274.5
—
0
20
5
39
1.30
0.23
2.2
3.3
41.3
42.9
%
—
5
39
5
42
1.20
0.22
1.4
1.6
—
—
—
0
0
67
637
1.13
0.21
4.4
3.4
—
—
—
0
0
14
118
1.21
0.20
1.3
1.7
1.3
1.4
%
0.18
14
101
12
133
0.89
0.08
2.0
2.1
—
—
—
0
0
19
202
0.93
0.06
5.6
3.9
14.2
10.2
mg/mmol
0.13
11
128
14
148
0.94
0.02
2.0
2.2
—
—
—
0
0
83
822
1.04
0.02
5.8
4.1
5.5
5.8
mmol/l
2.16
78
760
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
9
95
0.94
0.00
1.3
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
4.8
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_BEHCET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_BEHCET | 1.717 [1.24, 2.37] | 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 370 females with M13_BEHCET died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have M13_BEHCET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.128% | No data |
| 5 | 0.803% | No data |
| 10 | 2.061% | No data |
| 15 | 4.356% | No data |
| 20 | 7.527% | No data |
Relationships between endpoints
↥Index endpoint: M13_BEHCET – Behçet disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data